MA44909A - Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk - Google Patents

Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk

Info

Publication number
MA44909A
MA44909A MA044909A MA44909A MA44909A MA 44909 A MA44909 A MA 44909A MA 044909 A MA044909 A MA 044909A MA 44909 A MA44909 A MA 44909A MA 44909 A MA44909 A MA 44909A
Authority
MA
Morocco
Prior art keywords
inhibitor
btk
combinations
compositions
pharmaceutical compositions
Prior art date
Application number
MA044909A
Other languages
English (en)
Inventor
Brian Lannutti
Wayne Rothbaum
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MA44909A publication Critical patent/MA44909A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Des combinaisons thérapeutiques d'un inhibiteur de cd 19 et d'un inhibiteur de tyrosine kinase de bruton (btk) sont décrites. Dans certains modes de réalisation, l'invention concerne des compositions pharmaceutiques comprenant des combinaisons d'un inhibiteur de cd 19 et d'un inhibiteur de btk, ainsi que des procédés d'utilisation des compositions pharmaceutiques pour traiter une maladie, en particulier un cancer, tel qu'une hémopathie maligne. Combinaison d'un inhibiteur de btk et d'un inhibiteur de cd 19, telle qu'un anticorps ciblant cd19 ou un récepteur d'antigène chimérique ciblant cd19, exprimant un lymphocyte t ou une cellule nk, et ses compositions et leurs utilisations. Des combinaisons d'un inhibiteur de btk et d'un inhibiteur de cd 19 avec un inhibiteur programmé de mort-1 (pd-1) ou de pd-1 (pd-l1) et leurs compositions et leurs utilisations sont également décrites.
MA044909A 2015-09-15 2016-09-15 Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk MA44909A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218958P 2015-09-15 2015-09-15
US201562243646P 2015-10-19 2015-10-19
US201662277474P 2016-01-11 2016-01-11

Publications (1)

Publication Number Publication Date
MA44909A true MA44909A (fr) 2018-07-25

Family

ID=56990683

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044909A MA44909A (fr) 2015-09-15 2016-09-15 Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk

Country Status (10)

Country Link
US (1) US20240197742A1 (fr)
EP (2) EP3747472B1 (fr)
DK (1) DK3747472T3 (fr)
ES (1) ES2980794T3 (fr)
FI (1) FI3747472T3 (fr)
HU (1) HUE066644T2 (fr)
MA (1) MA44909A (fr)
PL (1) PL3747472T3 (fr)
PT (1) PT3747472T (fr)
WO (1) WO2017046747A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (fr) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Polythérapie anticancéreuse à base de smc
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
CN111163803B (zh) * 2017-08-11 2025-05-09 希望之城公司 表达car t细胞靶物的溶瘤病毒及其用途
CN107629994B (zh) * 2017-10-25 2021-11-02 中国科学院上海有机化学研究所 一种构建fk520高产工程菌株的方法和吸水链霉菌高产菌株
CN111019905A (zh) * 2018-09-12 2020-04-17 上海斯丹赛生物技术有限公司 Car修饰细胞及其在制备自身免疫性疾病药物中的应用
TWI907357B (zh) * 2019-09-05 2025-12-11 瑞典商阿斯特捷利康公司 用於治療晚期肺癌之組成物及方法
CN111053901B (zh) * 2019-12-18 2021-10-08 同济大学 一种具有聚集诱导发光特性的声敏剂及其制备方法
CN111476754B (zh) * 2020-02-28 2022-12-09 中国人民解放军陆军军医大学第二附属医院 一种骨髓细胞影像人工智能辅助分级诊断系统及方法
WO2021242614A1 (fr) * 2020-05-26 2021-12-02 Alexion Pharmaceuticals, Inc. Sous-populations de lymphocytes b circulants dans un lymphome à lymphocytes b indolent
CN111950187A (zh) * 2020-08-28 2020-11-17 桂林电子科技大学 一种优化微尺度csp焊点弯振耦合应力的方法
US20220168352A1 (en) * 2020-11-30 2022-06-02 Cytoagents, Inc. Car t-cell adjuvant therapies
CN114186708A (zh) * 2021-10-13 2022-03-15 华北电力大学 基于pso-elm循环流化床机组so2浓度预测方法
US20230242679A1 (en) * 2022-01-31 2023-08-03 Cytoagents, Inc. Bispecific antibody therapies
CN116703798B (zh) * 2023-08-08 2023-10-13 西南科技大学 基于自适应干扰抑制的食管多模态内镜图像增强融合方法
US12698512B2 (en) 2023-11-06 2026-08-04 City Of Hope Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
EP0401384B1 (fr) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
CA2326389C (fr) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Polypeptides specifiques a cd19 et cd3 et leurs utilisations
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
US6627442B1 (en) 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1383544A4 (fr) 2001-04-09 2007-12-12 Progenics Pharm Inc Immunotoxines anti-cd19
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
EP1314741B1 (fr) 2001-11-14 2007-03-07 Affimed Therapeutics AG Anticorps bispécifiques dirigés contre CD19 et CD16 et leur utilisation
DE10163755A1 (de) 2001-12-27 2004-01-08 Immugenics Ag Tumor-Peptidantigene aus humanem CD19-Protein
US20080260731A1 (en) 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2002950778A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of characterizing dendritic cells
WO2004104185A1 (fr) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation et isolement de lymphocytes t specifiques de l'antigene
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005007673A2 (fr) 2003-07-03 2005-01-27 Rush University Medical Center Peptides immunogenes
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
EP1904101A4 (fr) 2005-06-08 2011-06-15 Univ Duke Therapie a anticorps diriges contre cd19 a des fins de transplantation
WO2007002223A2 (fr) 2005-06-20 2007-01-04 Medarex, Inc. Anticorps cd19 et utilisations
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20070166306A1 (en) 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
US20090220501A1 (en) 2006-01-30 2009-09-03 Fey Georg H Anti-CD19 Antibody, Immunotoxin and Treatment Method
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2529621B1 (fr) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
WO2008109493A2 (fr) 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acides nucléiques conçus pour inhiber l'expression du gène cd19 et utilisations de ceux-ci
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
US7894450B2 (en) 2007-12-31 2011-02-22 Nortel Network, Ltd. Implementation of VPNs over a link state protocol controlled ethernet network
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CA2753158A1 (fr) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Anticorps humanises qui se fixent au cd19 et leurs utilisations
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
NZ598732A (en) 2009-10-27 2014-09-26 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody
EP3279215B1 (fr) 2009-11-24 2020-02-12 MedImmune Limited Agents de liaison ciblés contre b7-h1
WO2011147834A1 (fr) 2010-05-26 2011-12-01 Roche Glycart Ag Anticorps contre cd19 et utilisations associées
MX380504B (es) * 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9783578B2 (en) 2010-06-25 2017-10-10 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
PH12013500246A1 (en) 2010-08-10 2019-10-11 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
US8529202B2 (en) 2010-10-12 2013-09-10 General Electric Company System and method for turbine compartment ventilation
US20120141505A1 (en) 2010-11-01 2012-06-07 Fatih M. Uckun Cd19-ligand and use
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP5997252B2 (ja) 2011-04-04 2016-09-28 ファーマサイエンス・インコーポレイテッドＰｈａｒｍａｓｃｉｅｎｃｅ Ｉｎｃ． プロテインキナーゼ阻害剤
CA2760174A1 (fr) 2011-12-01 2013-06-01 Pharmascience Inc. Inhibiteurs de proteines kinases et leurs utilisations
ES2806142T3 (es) 2011-04-28 2021-02-16 Amgen Res Munich Gmbh Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 a pacientes en riesgo de posibles efectos adversos
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
EP2717895A1 (fr) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Composés thérapeutiques pour une immunomodulation
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
WO2013010869A1 (fr) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
EP2550975A1 (fr) 2011-07-29 2013-01-30 Sanofi Polythérapie pour le traitement de symptômes de malignités CD19+lymphocytes B comprenant un immunoconjugué anti-CD19 maytansinoïde et du rituximab
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
US20140303191A1 (en) * 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013074916A1 (fr) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Lymphocytes t car+ génétiquement modifiés pour éliminer l'expression du récepteur des lymphocytes t et/ou le système hla
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
EP2814846B1 (fr) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
WO2013132317A1 (fr) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Composés peptidomimétiques utilisés comme immunomodulateurs
CA2868121C (fr) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recepteurs d'antigene chimerique anti-mesotheline
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
PL4019041T3 (pl) 2012-07-13 2023-05-08 The Trustees Of The University Of Pennsylvania Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
KR20150063374A (ko) 2012-08-13 2015-06-09 안트로제네시스 코포레이션 자연 살해 세포 및 그의 용도
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
PL2989106T3 (pl) 2013-04-25 2017-08-31 Beigene, Ltd. Połączone związki heterocykliczne jako inhibitory kinazy białkowej
EP2997134B1 (fr) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Application à des humains de lymphocytes t comprenant un récepteur antigénique chimérique (car)
US20150005277A1 (en) 2013-06-28 2015-01-01 Beigene, Ltd. Protein Kinase Inhibitors and Uses Thereof
HUP1300432A2 (hu) 2013-07-10 2015-01-28 Tamas Kardos Downhill kerékpár szerkezet javított felfüggesztéssel
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
WO2015036927A1 (fr) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Dérivés peptidomimétiques d'immunomodulation
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
EP3076974A1 (fr) * 2013-12-05 2016-10-12 Acerta Pharma B.V. Association thérapeutique d'un inhibiteur de pi3k et d'un inhibiteur de btk
WO2015110923A2 (fr) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk
SG10202109752XA (en) * 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
AR103726A1 (es) * 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
US20180140602A1 (en) * 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives

Also Published As

Publication number Publication date
DK3747472T3 (da) 2024-06-10
HUE066644T2 (hu) 2024-08-28
PT3747472T (pt) 2024-06-05
PL3747472T3 (pl) 2024-08-05
FI3747472T3 (fi) 2024-06-03
US20240197742A1 (en) 2024-06-20
WO2017046747A1 (fr) 2017-03-23
EP3349798A1 (fr) 2018-07-25
ES2980794T3 (es) 2024-10-03
EP3747472B1 (fr) 2024-04-03
EP3747472A1 (fr) 2020-12-09

Similar Documents

Publication Publication Date Title
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA71118B1 (fr) Anticorps anti-c5 et leurs utilisations
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MA52742B1 (fr) Anticorps bispécifiques dll3-cd3
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA52773B1 (fr) Anticorps anti-cd3 et leurs utilisations
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA45280B1 (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
MA58293B1 (fr) Molécules de liaison pd-1 et leurs procédés d'utilisation
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
MA49727A (fr) Anticorps et polypeptides dirigés contre cd127
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA39313B1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MA44146B1 (fr) Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA33811B1 (fr) Composés et méthodes utilisés pour la modulation kinases et indications à cet effet
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MA32713B1 (fr) Anticorps anti-egfr/anti-igf-1r bispecifiques
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
WO2019032945A9 (fr) Agent liant cd40 et utilisations associées